Management of Autoimmune Skin Diseases

Principles & Corticosteroids - First-Line Firefight

• Management Goals:
  • Induce remission (rapid control).
  • Maintain remission, prevent flares.
  • Minimize treatment side effects.
  • Enhance Quality of Life (QoL).
• Corticosteroids (CS): First-line; potent anti-inflammatory, immunosuppressive.
  • Topical CS:
    • Potency (mild to superpotent) based on site & severity.
    • E.g., Hydrocortisone (face), Clobetasol (palms/soles).
    • SE: Atrophy, striae, telangiectasia, tachyphylaxis.
  • Systemic CS: For severe/widespread disease.
    • Oral Prednisolone: 1-2 mg/kg/day initially, then slow taper.
    • IV Pulse Therapy (e.g., Dexamethasone-Cyclophosphamide Pulse - DCP) for aggressive forms like Pemphigus.
    • SE: Cushing's, osteoporosis, ↑infection risk, HPA axis suppression, PUD.
    • Monitor: BP, glucose, electrolytes.
  • Intralesional CS (ILCS): Localized lesions (e.g., DLE, keloids). Triamcinolone acetonide (2.5-10 mg/mL).

⭐ Prednisolone 1-1.5 mg/kg/day is the initial standard for Pemphigus Vulgaris to achieve rapid blister control.

Steroid-Sparing Agents - Backup Brigade Buddies

Use: ↓ steroids, maintain remission. Monitor labs per agent.

• Azathioprine (AZA)
  • Purine analogue. 1-3 mg/kg/d. Onset: 6-12w.
  • SE: Myelosuppression (check TPMT), hepatotoxic, pancreatitis. ⭐ > TPMT testing vital before Azathioprine: prevents severe myelosuppression in at-risk patients.
• Methotrexate (MTX)
  • Folate antagonist. 7.5-25 mg/wk (+folic acid). Onset: 4-8w.
  • SE: Myelosuppression, hepatotoxic, pneumonitis, teratogen.
• Mycophenolate Mofetil (MMF)
  • IMPDH inhibitor. 1-2 g/d. Onset: 4-8w.
  • SE: GI upset, myelosuppression.
• Cyclosporine (CsA)
  • Calcineurin inhibitor. 2.5-5 mg/kg/d. Onset: 2-4w (rapid).
  • SE: Nephrotoxic, HTN, neurotoxic.
• Cyclophosphamide (CYC) (Severe cases)
  • Alkylating agent.
  • SE: Myelosuppression, hemorrhagic cystitis, infertility, malignancy.
• Dapsone
  • Anti-inflammatory. 50-200 mg/d.
  • SE: Hemolysis (check G6PD), methemoglobinemia.

Biologics & IVIG - Precision Power-Ups

• Biologics: Target refractory autoimmune skin diseases.
  • Mechanism: Target specific cytokines or immune cells.
  • Key Examples (Disease):
    • TNF-α inhibitors (Infliximab): Psoriasis, HS.
    • IL-17 inhibitors (Secukinumab): Psoriasis.
    • IL-23 inhibitors (Guselkumab): Psoriasis.
    • Rituximab (anti-CD20): Pemphigus Vulgaris (PV), Bullous Pemphigoid (BP).
    • Omalizumab (anti-IgE): Chronic Spontaneous Urticaria (CSU).
  • Pre-therapy screening: TB, Hepatitis B/C.
• IVIG (Intravenous Immunoglobulin):
  • Mechanism: Broad immunomodulatory effects.
  • Uses: Severe PV, BP, Dermatomyositis.
  • Dose: 0.4-2 g/kg per cycle.
  • Adverse Effects: Headache, renal toxicity (sucrose preps), thrombosis.

⭐ Rituximab significantly reduces steroid dependence in Pemphigus Vulgaris.

Adjunctive Care - Holistic Healing Hints

• Sun Protection: Crucial for photosensitive conditions (e.g., SLE, dermatomyositis).
  • Broad-spectrum sunscreen (SPF >30, PA+++).
  • Protective clothing, seek shade.
• Gentle Skincare:
  • Mild, non-irritant cleansers.
  • Regular use of emollients/moisturizers to maintain skin barrier.
• Diet & Lifestyle:
  • Balanced nutrition; address deficiencies (e.g., Vitamin D).
  • Smoking cessation (worsens many conditions, e.g., DLE, psoriasis).
  • Stress reduction techniques (yoga, meditation).
• Psychological Support: Address anxiety/depression common with chronic skin disease.
• Physiotherapy: For joint involvement or contractures (e.g., scleroderma).
• Vaccinations: Update as per guidelines, especially for immunosuppressed patients (avoid live vaccines during active immunosuppression).

⭐ Vitamin D supplementation is often recommended in autoimmune diseases due to its immunomodulatory effects and high prevalence of deficiency, particularly in patients with limited sun exposure or on corticosteroids. Monitor levels; aim for >30 ng/mL.

• Regular Monitoring: For disease activity, treatment side effects, and associated comorbidities (e.g., thyroid disease in vitiligo).

High‑Yield Points - ⚡ Biggest Takeaways

• Topical and systemic corticosteroids are primary for acute control.
• Immunosuppressants (azathioprine, methotrexate, MMF) act as crucial steroid-sparing agents.
• Rituximab shows high efficacy in refractory Pemphigus Vulgaris.
• Bullous Pemphigoid typically responds to potent topical steroids or moderate systemic doses.
• Dapsone is the mainstay treatment for Dermatitis Herpetiformis.
• Hydroxychloroquine is key for managing Cutaneous Lupus Erythematosus.
• Vigilant monitoring for adverse effects of immunosuppressive therapy is essential.